Theratechnologies Inc T.TH

New article published

[scarlet1967]

https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.15086

[qwerty22]

 

[Wino115]

Would like to read this too. I think they did show us the photos of the metastasizes on lung samples which backed up their statement  (the pre and post administration on Th1902). But you're right, they never specifically identified lymph node metastices for mTNBC. From what I gather, that is the most prevalent location.  Would be interesting to know if somethings happening in the

[qwerty22]

That's a different thing, this sounds like data where they've gone to actual human patients tumour material and screened it for Sortilin then matched those Sortilin levels to the patients disease and outcomes. It's a bit like a number of other science papers that have looked for Sortilin in various cancer patients. It might be an expansion on those microarray results if those

[jfm1330]

The link between sortilin and the metastatic potential was known in breast cancer. In this article that I had already given the reference of, when I looked into Sortina's approach, they made experiments on a specific type of TNBC, a subtype called ER-alpha-positive brest cancer. I still belive that the key to great efficacy results will be selection of patients with cancers overexpressing

[qwerty22]

"I still belive that the key to great efficacy results will be selection of patients with cancers overexpressing sortilin" Sure. And the key to higher sales is the largest possible target population. It's a trade-off where I believe you aim for the largest population that gives an acceptable ('approveable') response. Cash wins! So if efficacy looks weak they might be

[scarlet1967]

Cash always wins, I fully agree if the drug shows efficacy in bigger groups of patients that should be their target. I speculated while ago also what if what if the ratio of conjugation to the receptor is high enough so they can target lower stages of cancer with less expression of sortilin. That would be even a bigger trade off as not only the market gets bigger but also patients stay on the drug

[scarlet1967]

Coming soon... https://www.linkedin.com/posts/theratechnologies-inc_th1902-a-new-docetaxelpeptide-conjugate-activity-6826511762628726785-lR28